Locations:
Search IconSearch
April 19, 2019/Cancer

Trends in Stereotactic Laser Ablation for Brain Tumors: Mounting Experience and Enhanced Technology Are Boosting Outcomes

Insights from 240 cases over 8 years at Cleveland Clinic

19-NEU-446-stereotactic-laser-ablation-brain-tumor-650×450

Outcomes and operative times associated with stereotactic laser ablation for treating brain tumors dramatically improved over the past eight years at a single institution even as the procedure was increasingly used to treat metastases and radiation necrosis from radiosurgery failure. These findings — from a retrospective review of 240 Cleveland Clinic patients since 2011 — were detailed in a platform presentation this week at the 2019 annual scientific meeting of the American Association of Neurological Surgeons.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“Cleveland Clinic was one of the early adopters of stereotactic laser ablation treatment for brain tumors, so we have good data starting in 2011, when the technology became commercially available after FDA approval,” says the study’s principal investigator, Alireza M. Mohammadi, MD, a neurosurgeon with Cleveland Clinic’s Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center. “Assessing our experience allows us to detect important trends and develop evidence-based best practices for other centers with more limited experience to follow.”

Study design and findings

The study categorized patients into two time periods for comparison: the early period, from 2011 to 2014 (including 102 patients), and the more recent period, from 2015 to 2018 (138 patients). Extensive data on patient demographics, surgical and tumor characteristics, and temporary and permanent complications (the latter defined as unresolved after 6 months) were assessed.

The following differences were detected between the early and recent periods:

  • Tumor types changed. In the early years, stereotactic laser ablation was predominantly used for upfront and recurrent gliomas (76.6%). Over time, utilization markedly increased for treating metastases and radiation necrosis following radiosurgery failure, changing from 25 combined cases (23.4%) in the early years to 58 cases (42.6%) in recent years.
  • Operative time shortened, from 6.25 hours in the early years to 3.6 hours in recent years.
  • Complication rates improved. Rates of permanent postoperative deficits declined from 15% to 4%, a significant change. Dr. Mohammadi says this decline was likely due in part to modification of the team’s surgical techniques, following review of the initial series of cases, to protect eloquent brain area close to the tumor and laser field (Neurosurg Focus. 2016;41:E11). “Additionally, there were no cases of infection or large hemorrhage needing surgery in the second cohort,” he notes.
  • Postoperative mortality and severe morbidity decreased. Mortality improved from 4.2% in the early group to 1.5% in the recent period.

Advertisement

Dr. Mohammadi credits these substantial changes over the years to growing experience on the part of the multidisciplinary team as well as evolving technology. In 2013, a new generation of the state-of-the-art stereotactic laser ablation device (NeuroBlate® System) became available, allowing more efficient delivery of energy from the laser probe as well as improved planning and placement of the laser probe into the tumor.

Most common applications

Stereotactic laser ablation is a powerful tool that plays an increasing role in treating challenging brain tumors and their complications, Dr. Mohammadi notes. Some of the most important evolving applications include:

  • Radiation necrosis. Radiation necrosis is a frequent complication of radiosurgery for brain metastases, occurring in about 10% to 15% of cases, often causing neurological deterioration. A multicenter study led by Cleveland Clinic (J Neurosurg. 2018;130:804-811) found that stereotactic laser ablation offers good control for radiation necrosis, resulting in stabilized performance and preserved quality of life and cognition.
  • High-grade gliomas. Complete resection of difficult-to-access high-grade gliomas is rarely achievable surgically, according to Dr. Mohammadi, who served as lead author on a multicenter study assessing the role of stereotactic laser ablation for these tumors (Cancer Med. 2014;3:971-979 and Neurosurgery. 2018 Nov 23 [Epub ahead of print]). Laser ablation was shown to be safe and effective in this setting.

“We now have enough evidence to confidently say that stereotactic laser ablation can fill important roles for treating primary and metastatic brain tumors and radiation necrosis,” says Dr. Mohammadi. “We expect its uses to continue to evolve as technology advances, further enhancing our capabilities.”

Advertisement

Related Articles

Surgeon
June 30, 2025/Cancer/News & Insight
Potential for Deintensification of Surgical Interventions in Low-Risk Breast Cancer

Reconsidering axillary lymph node dissection as well as depth of surgical margins

Dendritic cell
June 26, 2025/Cancer/News & Insight
Avelumab Induces Natural Killer Cell Activation and Dendritic Cell Crosstalk

Researchers uncover profound differences in the mechanism of action between different PD-L1 checkpoint inhibitors

World map
June 19, 2025/Cancer/News & Insight
Breaking Barriers to Cancer Care: Cleveland Clinic’s Global Approach

A multi-pronged strategy for tackling cancer access problems

CAR T-cell therapy illustration
June 12, 2025/Cancer/News & Insight
First-Ever U.S. Trial of CAR T-Cell Therapy for Relapsed/Refractory AL Amyloidosis

Early results show patients experiencing deep and complete response

Genomic profiling
June 10, 2025/Cancer
Cleveland Clinic’s Hemato-Oncology Team Spearheads the Development of Guidelines for Genomic Profiling of MDS to Inform Allo-HCT

Inclusion of genomic profiling and risk factors recommended for treatment planning

scan showing cholangiocarcinoma
June 5, 2025/Cancer/News & Insight
Exploring Novel Therapeutic Avenues in Advanced Cholangiocarcinoma: Lessons from the EA2187 Trial

Collaborative research effort underscores the urgent need for effective second-line therapies in this rare, aggressive cancer

Anticoagulant sign
June 4, 2025/Cancer/News & Insight
Direct-Acting Oral Anticoagulants Safe for Patients with Brain Metastasis

Largest study to date comparing direct-acting oral anticoagulants to low-molecular-weight heparin

Ad